Shopping Cart 0
Cart Subtotal
AED 0

National Institute of Neurological Disorders and Stroke - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

National Institute of Neurological Disorders and Stroke (NINDS), a subsidiary of National Institutes of Health is a healthcare research institute that conducts and supports research on brain and nervous system disorders. The institute's clinical research areas include Alzheimer's disease, brain tumors, developmental disorders stroke, epilepsy, Parkinson's disease, traumatic brain injury, stem cell research, health disparities research, bioengineering research and autism, among others. Its activities comprise training of investigators in basic and clinical neurosciences, and seeks better understanding, diagnosis, treatment, and prevention of neurological disorders. NINDS' serves scientists, clinicians, and the public. The Institute collaborates with other NIH components, federal agencies, and with voluntary professional and commercial organizations. NINDS is headquartered in Bethesda, Maryland, the US.

National Institute of Neurological Disorders and Stroke-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Matinas BioPharma and National Institute of Neurological Disorders and Stroke Enter into Research Agreement 11

ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 12

Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 13

Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 14

Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 15

Licensing Agreements 16

Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 16

National Institute of Neurological Disorders and Stroke-Key Competitors 17

National Institute of Neurological Disorders and Stroke-Key Employees 18

National Institute of Neurological Disorders and Stroke-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Government and Public Interest 20

Sep 18, 2018: Potential drugs for ALS, Alzheimer's and Parkinson's garner USD 3 million grant 20

Sep 05, 2018: USD 45 million clinical trial to test sleep apnea treatment in stroke survivors nationwide 21

Aug 30, 2018: Study provides an early recipe for rewiring spinal cords 22

Aug 28, 2018: NIH research program to explore the transition from acute to chronic pain 24

Aug 21, 2018: Cleveland Clinic Researchers Discover Novel Subtype of Multiple Sclerosis 25

Jul 25, 2018: Protein affected by rare Parkinson's mutation may lurk behind many cases of the disease 26

Jul 24, 2018: Yale selected as one of 25 clinical trial sites for treatment of neurological diseases 28

Jun 07, 2018: Genes linked to Alzheimer's contribute to damage in different ways 29

May 29, 2018: Self-tuning brain implant could help treat patients with Parkinson's disease 30

May 10, 2018: GW Participates in Study that Supports Revised AHA Hypertension Guidelines 31

May 07, 2018: Scientists discover roadblocks that stop brain white matter healing 32

Apr 16, 2018: Batrakova Gets USD 1.7 Million Grant to Treat Parkinson's with Cell-Delivered Gene Therapy 33

Apr 12, 2018: Scientists teach computers how to analyze brain cells 34

Mar 13, 2018: NIH scientists search for the clocks behind aging brain disorders 36

Feb 27, 2018: College of Pharmacy Granted USD 1.7 Million Toward Epilepsy Research 37

Feb 15, 2018: Specific set of nerve cells controls seizures' spread through brain 39

Feb 09, 2018: BRAIN grant funds study of neurocircuitry of depression 41

Dec 19, 2017: Protein Levels Linked to Parkinson's Gait Difficulty and Cognitive Problems 42

Nov 06, 2017: The Wistar Institute Awarded More Than USD 16.5M in Grants to Fund Cancer & Infectious Disease Research and Training 43

Oct 31, 2017: NIH: Study shows how memories ripple through the brain 45

Oct 26, 2017: Scientists find a role for Parkinson's gene in the brain 46

Oct 23, 2017: Penn Radiology Researcher Awarded USD 3.9 Million to Help Develop First Three-Dimensional Digital Atlas of Brain Cells 47

Oct 18, 2017: New insight into how brain cells die in Alzheimer's disease and FTD 48

Oct 02, 2017: CU Researchers win prestigious USD 2 million NIH grant for brain study 50

Sep 20, 2017: Researchers hit the brakes on lethal brain cancers in mice 51

Sep 20, 2017: Immune cells may heal bleeding brain after strokes 52

Sep 07, 2017: NIH awards nearly USD 100 million for Autism Centers of Excellence program 54

Aug 18, 2017: Nortis Awarded USD 688K NIH Phase II SBIR Fast Track Grant to Develop Living Model of Human Blood-Brain Barrier 56

Aug 15, 2017: New USD 1.9M federal grant to fund JAX studies of microbiome's role in multiple sclerosis 57

Jul 06, 2017: NIH and Collaborators Identify the Genomic Cause for Carey-Fineman-Ziter Syndrome 58

Jun 21, 2017: Researchers uncover genetic gains and losses in Tourette syndrome 60

Jun 20, 2017: BlackThorn Therapeutics to Receive Up to USD 8 Million in NIH Blueprint Neurotherapeutics Network Funding to Advance Kappa Opioid Receptor Antagonist Program 61

Jan 26, 2017: NIH initiates pilot grant program for innovative neurological research 62

Product News 66

Aug 14, 2018: How drugs could repair damage from Multiple Sclerosis 66

Other Significant Developments 67

Jul 24, 2018: NIH renews NeuroNEXT for neurological clinical research 67

Appendix 68

Methodology 68

About GlobalData 68

Contact Us 68

Disclaimer 68


List Of Figure

List of Figures

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Key Facts 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute of Neurological Disorders and Stroke, Deals By Therapy Area, 2012 to YTD 2018 9

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Matinas BioPharma and National Institute of Neurological Disorders and Stroke Enter into Research Agreement 11

ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 12

Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 13

Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 14

Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 15

Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 16

National Institute of Neurological Disorders and Stroke, Key Competitors 17

National Institute of Neurological Disorders and Stroke, Key Employees 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

National Institute of Neurological Disorders and Stroke, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

National Institute of Neurological Disorders and Stroke (NINDS), a subsidiary of National Institutes of Health is a healthcare research institute that conducts and supports research on brain and nervous system disorders. The institute's clinical research areas include Alzheimer's disease, brain tumors, developmental disorders stroke, epilepsy, Parkinson's disease, traumatic brain injury, stem cell research, health disparities research, bioengineering research and autism, among others. Its activities comprise training of investigators in basic and clinical neurosciences, and seeks better understanding, diagnosis, treatment, and prevention of neurological disorders. NINDS' serves scientists, clinicians, and the public. The Institute collaborates with other NIH components, federal agencies, and with voluntary professional and commercial organizations. NINDS is headquartered in Bethesda, Maryland, the US.

National Institute of Neurological Disorders and Stroke-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Matinas BioPharma and National Institute of Neurological Disorders and Stroke Enter into Research Agreement 11

ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 12

Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 13

Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 14

Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 15

Licensing Agreements 16

Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 16

National Institute of Neurological Disorders and Stroke-Key Competitors 17

National Institute of Neurological Disorders and Stroke-Key Employees 18

National Institute of Neurological Disorders and Stroke-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Government and Public Interest 20

Sep 18, 2018: Potential drugs for ALS, Alzheimer's and Parkinson's garner USD 3 million grant 20

Sep 05, 2018: USD 45 million clinical trial to test sleep apnea treatment in stroke survivors nationwide 21

Aug 30, 2018: Study provides an early recipe for rewiring spinal cords 22

Aug 28, 2018: NIH research program to explore the transition from acute to chronic pain 24

Aug 21, 2018: Cleveland Clinic Researchers Discover Novel Subtype of Multiple Sclerosis 25

Jul 25, 2018: Protein affected by rare Parkinson's mutation may lurk behind many cases of the disease 26

Jul 24, 2018: Yale selected as one of 25 clinical trial sites for treatment of neurological diseases 28

Jun 07, 2018: Genes linked to Alzheimer's contribute to damage in different ways 29

May 29, 2018: Self-tuning brain implant could help treat patients with Parkinson's disease 30

May 10, 2018: GW Participates in Study that Supports Revised AHA Hypertension Guidelines 31

May 07, 2018: Scientists discover roadblocks that stop brain white matter healing 32

Apr 16, 2018: Batrakova Gets USD 1.7 Million Grant to Treat Parkinson's with Cell-Delivered Gene Therapy 33

Apr 12, 2018: Scientists teach computers how to analyze brain cells 34

Mar 13, 2018: NIH scientists search for the clocks behind aging brain disorders 36

Feb 27, 2018: College of Pharmacy Granted USD 1.7 Million Toward Epilepsy Research 37

Feb 15, 2018: Specific set of nerve cells controls seizures' spread through brain 39

Feb 09, 2018: BRAIN grant funds study of neurocircuitry of depression 41

Dec 19, 2017: Protein Levels Linked to Parkinson's Gait Difficulty and Cognitive Problems 42

Nov 06, 2017: The Wistar Institute Awarded More Than USD 16.5M in Grants to Fund Cancer & Infectious Disease Research and Training 43

Oct 31, 2017: NIH: Study shows how memories ripple through the brain 45

Oct 26, 2017: Scientists find a role for Parkinson's gene in the brain 46

Oct 23, 2017: Penn Radiology Researcher Awarded USD 3.9 Million to Help Develop First Three-Dimensional Digital Atlas of Brain Cells 47

Oct 18, 2017: New insight into how brain cells die in Alzheimer's disease and FTD 48

Oct 02, 2017: CU Researchers win prestigious USD 2 million NIH grant for brain study 50

Sep 20, 2017: Researchers hit the brakes on lethal brain cancers in mice 51

Sep 20, 2017: Immune cells may heal bleeding brain after strokes 52

Sep 07, 2017: NIH awards nearly USD 100 million for Autism Centers of Excellence program 54

Aug 18, 2017: Nortis Awarded USD 688K NIH Phase II SBIR Fast Track Grant to Develop Living Model of Human Blood-Brain Barrier 56

Aug 15, 2017: New USD 1.9M federal grant to fund JAX studies of microbiome's role in multiple sclerosis 57

Jul 06, 2017: NIH and Collaborators Identify the Genomic Cause for Carey-Fineman-Ziter Syndrome 58

Jun 21, 2017: Researchers uncover genetic gains and losses in Tourette syndrome 60

Jun 20, 2017: BlackThorn Therapeutics to Receive Up to USD 8 Million in NIH Blueprint Neurotherapeutics Network Funding to Advance Kappa Opioid Receptor Antagonist Program 61

Jan 26, 2017: NIH initiates pilot grant program for innovative neurological research 62

Product News 66

Aug 14, 2018: How drugs could repair damage from Multiple Sclerosis 66

Other Significant Developments 67

Jul 24, 2018: NIH renews NeuroNEXT for neurological clinical research 67

Appendix 68

Methodology 68

About GlobalData 68

Contact Us 68

Disclaimer 68


List Of Figure

List of Figures

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Key Facts 2

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

National Institute of Neurological Disorders and Stroke, Deals By Therapy Area, 2012 to YTD 2018 9

National Institute of Neurological Disorders and Stroke, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Matinas BioPharma and National Institute of Neurological Disorders and Stroke Enter into Research Agreement 11

ConverGene Enters into Development Agreement with National Institute of Neurological Disorders and Stroke 12

Geneuro Enters into Agreement with National Institute of Neurological Disorders and Stroke 13

Thrombolytic Science Enters into Agreement with National Institute of Neurological Disorders and Stroke 14

Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 15

Cogentis Therapeutics to Enter into Licensing Agreement with National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services 16

National Institute of Neurological Disorders and Stroke, Key Competitors 17

National Institute of Neurological Disorders and Stroke, Key Employees 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

National Institute of Neurological Disorders and Stroke, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

chat_bubbleLet's Chat